Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology

Eur J Pharm Biopharm. 2008 Sep;70(1):98-108. doi: 10.1016/j.ejpb.2008.03.015. Epub 2008 Mar 31.

Abstract

It seems well established that CpG oligonucleotide Th1-biased adjuvant activity can be improved when closely associated with a variety of antigens in, for example, microparticles. In this context, we prepared 1-micron near non-charged poly(lactic-co-glycolic) acid (PLGA) 502 and PLGA 756 microparticles that loaded with high-efficiency antigen (50% ovalbumin (OVA), approximately) into their matrix and CpG-chitosan complexes (near to 20%) onto their surface maintaining OVA and CpG integrity intact. In the intradermal immunization studies, whereas OVA microencapsulated into PLGA 756 alone induced a strong humoral immune response assisted by a very clear Th1 bias (IgG2a/IgG1=0.88) that was decreased by CpG co-delivery (IgG2a/IgG1=0.55), the co-encapsulation of CpG with OVA in PLGA 502 particles significantly improved the antibody response and isotype shifting (IgG2a/IgG1=0.73) in comparison with mice immunized with OVA-loaded PLGA 502 (IgG2a/IgG1=0). This improvement was not correlated with the cellular immune response where the effect of co-encapsulated CpG was rather negative (2030 and 335 pg/mL IFN-gamma for OVA PLGA 502 and OVA CpG PLGA 502, respectively). These results underscore the critical role of polymer nature and microparticle characteristics to show the benefits of co-encapsulating CpG motifs in close proximity with an antigen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antibodies / blood
  • Antibody Formation / drug effects
  • Antigens / administration & dosage
  • Antigens / chemistry
  • Antigens / pharmacology*
  • Cells, Cultured
  • Chemistry, Pharmaceutical
  • Chitosan / chemistry
  • Dendritic Cells / drug effects
  • Dendritic Cells / immunology
  • Drug Carriers*
  • Female
  • Immunity, Cellular / drug effects
  • Injections, Intradermal
  • Interferon-gamma / blood
  • Interleukin-4 / blood
  • Lactic Acid / chemistry*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Oligodeoxyribonucleotides / administration & dosage
  • Oligodeoxyribonucleotides / chemistry
  • Oligodeoxyribonucleotides / pharmacology*
  • Ovalbumin / chemistry*
  • Particle Size
  • Polyglycolic Acid / chemistry*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Solubility
  • Technology, Pharmaceutical / methods*
  • Th1 Cells / drug effects
  • Th1 Cells / immunology
  • Time Factors
  • Vaccines / administration & dosage
  • Vaccines / chemistry
  • Vaccines / pharmacology*

Substances

  • Adjuvants, Immunologic
  • Antibodies
  • Antigens
  • CPG-oligonucleotide
  • Drug Carriers
  • Oligodeoxyribonucleotides
  • Vaccines
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Interleukin-4
  • Polyglycolic Acid
  • Lactic Acid
  • Interferon-gamma
  • Ovalbumin
  • Chitosan